

Exhibit 1

**UNITED STATES BANKRUPTCY COURT
 SOUTHERN DISTRICT OF NEW YORK**

In re:	:	Chapter 11
	:	
PURDUE PHARMA L.P., <i>et al.</i> ,	:	Case No. 19-23649 (RDD)
	:	
Debtors. ¹	:	(Jointly Administered)
	:	

**FIRST MONTHLY FEE STATEMENT OF KPMG LLP FOR COMPENSATION
 FOR SERVICES RENDERED AND REIMBURSEMENT OF EXPENSES
 INCURRED AS TAX CONSULTANT FOR THE DEBTORS
 AND THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS
 FOR THE PERIOD FROM DECEMBER 23, 2019 THROUGH JANUARY 31, 2020**

Name of Applicant:	KPMG LLP
Authorized to Provide Professional Services to:	The Debtors and the Official Committee of Unsecured Creditors
Date of Retention:	February 24, 2020, <i>nunc pro tunc</i> to December 23, 2019
Period for Which Compensation and Reimbursement is Sought:	December 23, 2019 through January 31, 2020
Amount of Compensation Sought as Actual, Reasonable, and Necessary:	\$ 580,539.30
Less 20% Holdback:	\$ (116,107.86)
Amount of Expense Reimbursement Sought as Actual, Reasonable, and Necessary:	\$ 614.93
Total Fees and Expenses Due:	\$ 465,046.37

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

EXHIBIT A

Purdue Pharma L.P.

Case No. 19-23649

Summary Of Hours and Discounted Fees Incurred By Professional
 December 23, 2019 through January 31, 2020

Professional Person	Position & Department	Country of Origin	Total Billed Hours	Hourly Billing Rate	Total Compensation
Andy Farinich	Senior Associate - International Tax	US	65.4	\$ 534	\$ 34,923.60
Anja Poesl	Senior Manager - German Intl Tax	US	5.8	\$ 750	\$ 4,350.00
Arik Eytan	Partner - Tax	Israel	1.8	\$ 555	\$ 999.00
Aroen Rambhadjan	Partner - Tax	Netherlands	1.8	\$ 985	\$ 1,773.00
Arpit Desai	Senior Manager - Tax	UK	4.0	\$ 750	\$ 3,000.00
Arpit Kakar	Senior Associate - Tax	India	2.8	\$ 640	\$ 1,792.00
Ashley Armfield	Senior Associate - M&A Tax	US	138.2	\$ 534	\$ 73,798.80
Carlotta Bertu	Senior Associate - Tax	Italy	0.6	\$ 640	\$ 384.00
Casey Nunez	Senior Manager - M&A Tax	US	32.7	\$ 744	\$ 24,328.80
Christian Schmid	Partner - Int'l Tax	Germany	5.5	\$ 985	\$ 5,417.50
Christin Witt	Manager - German Intl' Tax	US	0.4	\$ 650	\$ 260.00
Danielle Moloughney	Associate - Tax	Canada	1.6	\$ 172	\$ 275.20
Dawn Krishnamurthy	Manager - M&A Tax	US	150.7	\$ 695	\$ 104,736.50
Devon Rowles	Associate - M&A Tax	US	125.0	\$ 350	\$ 43,750.00
Dong-Ju Shin	Senior Manager - Global Tax	South Korea	0.5	\$ 750	\$ 375.00
Douglas Holland	Principal - Washington National Tax	US	1.1	\$ 985	\$ 1,083.50
Frank Caratzola	Senior Associate - Intl' Tax	US	20.7	\$ 534	\$ 11,053.80
Gavin Little	Managing Director - Tax	UK	2.3	\$ 985	\$ 2,265.50
Gregory Bell	Partner - Tax	Canada	1.5	\$ 743	\$ 1,114.50
Howard Steinberg	Partner - M&A Tax	US	27.4	\$ 856	\$ 23,454.40
Isaac Hirsch	Managing Director - Int'l Tax	US	79.1	\$ 819	\$ 64,782.90
Jess Commisso	Associate - M&A Tax	US	170.1	\$ 350	\$ 59,535.00
Jonas Lau	Senior Manager - Tax	Canada	5.5	\$ 614	\$ 3,377.00
Karen Erickson	Senior Manager - Tax	US	5.6	\$ 690	\$ 3,864.00
Karl Tong	Manager - Tax	China	0.3	\$ 594	\$ 178.20
Kees Van Meel	Principal - Int'l Tax	US	0.5	\$ 757	\$ 378.50
Kyung-Min Kim	Senior Manager - Tax	South Korea	1.0	\$ 750	\$ 750.00
Lorenzo Bellavite	Partner - Tax	Italy	0.5	\$ 985	\$ 492.50
Lukas van der Veen	Manager - Tax	Netherlands	7.2	\$ 730	\$ 5,256.00
Madeleine Latham	Associate - Tax	UK	4.4	\$ 380	\$ 1,672.00
Maggie Scully	Associate - M&A Tax	US	3.1	\$ 350	\$ 1,085.00
Mark Hoffenberg	Principal - Washington National Tax	US	6.3	\$ 980	\$ 6,174.00
Michael Land	Senior Associate - M&A Tax	US	111.7	\$ 534	\$ 59,647.80
Monica Plangman	Associate Director - Bankruptcy	US	3.6	\$ 264	\$ 950.40
Naman Gupta	Senior Associate - Tax	India	3.1	\$ 640	\$ 1,984.00
Nick Morgan	Associate - M&A Tax	US	12.9	\$ 350	\$ 4,515.00
Nidhi Jain	Senior Associate - Tax	India	3.5	\$ 640	\$ 2,240.00
Oron Zeevi	Senior Manager - Tax	Israel	5.5	\$ 450	\$ 2,475.00
Paul Kunkel	Senior Manager - Washington National Tax	US	1.4	\$ 744	\$ 1,041.60
Pete DiMatteo	Manager - Int'l Tax	US	93.4	\$ 650	\$ 60,710.00
Philipp Reer	Partner - German Intl Tax	US	4.5	\$ 765	\$ 3,442.50
Renay Gosen	Associate - M&A Tax	US	3.2	\$ 350	\$ 1,120.00
Sam Tyler	Partner - Tax	Canada	3.2	\$ 743	\$ 2,377.60
Sonia Stricker	Associate - Tax	Germany	28.3	\$ 380	\$ 10,754.00

Summary Of Hours and Discounted Fees Incurred By Professional
December 23, 2019 through January 31, 2020

Professional Person	Position & Department	Country of Origin	Total Billed Hours	Hourly Billing Rate	Total Compensation
Thomas Giordano	Associate - Int'l Tax	US	148.3	\$ 350	\$ 51,905.00
Thomas Heubach	Senior Manager - Tax	Germany	23.5	\$ 750	\$ 17,625.00
Tracy Stone	Principal - Washington National Tax	US	1.3	\$ 906	\$ 1,177.80
Wendy Shaffer	Manager - Bankruptcy	US	33.7	\$ 202	\$ 6,807.40
Less 50% Rate Reduction related to Non-Working Travel Time					\$ (2,457.00)
Subtotal of Hours and Discounted Fees			1,354.5		\$ 712,996.30
Less KPMG Voluntary Reduction (See Exhibit C1)					\$ (130,000.00)
Less KPMG Voluntary Reduction (See Exhibit C2)					\$ (2,457.00) ⁽¹⁾
Total Discounted Fees					\$ 580,539.30
Total Out of Pocket Expenses					\$ 989.04
Voluntary Reduction in Expenses					\$ (374.11)
Total Out of Pocket Expenses After Voluntary Reduction					\$ 614.93 ⁽²⁾
Total Fees and Out of Pocket Expenses					\$ 581,154.23
Less Holdback Adjustment (20%)					\$ (116,107.86)
Net Requested Fees & Out of Pocket Expenses					\$ 465,046.37
Blended Hourly Rate				\$ 428.60	

⁽¹⁾ KPMG is taking a voluntary reduction of non-working travel time.

⁽²⁾ See Exhibit D and D1 for an explanation of the expenses and the voluntary reduction.

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Jess Commisso	12/31/19	Updating virtual data room (VDR) tracker / revenue breakdown with regards to additional documentation received as of 12/31 to update our Mundipharma jurisdiction revenue breakdown - pursuant to determining priority jurisdictions for assistance by KPMG member firms.	1.9	\$ 350	\$ 665.00
Devon Rowles	12/31/19	Continued (from 12/30) to track designated portion of revenue for numerous Mundipharma entities in financial statements for years 2016, 2017, 2018 pursuant to prioritizing jurisdictions for future tax analysis.	3.3	\$ 350	\$ 1,155.00
Jess Commisso	12/31/19	Continued (from 12/30) to review assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.	3.9	\$ 350	\$ 1,365.00
Dawn Krishnamurthy	01/02/20	0.1 Manager review of draft email to KPMG member firms requesting their high priority tax information requests; 0.3 Review of Purdue Term Sheet filed on docket for purpose of gaining insight regarding potential tax issues related to proposed transactions.	0.4	\$ 695	\$ 278.00
Ashley Armfield	01/02/20	Review of latest version of Purdue Information Request List and concurrently providing comments to M. Land (KPMG).	0.6	\$ 534	\$ 320.40
Pete DiMatteo	01/02/20	Review draft information request list from an international tax perspective	0.7	\$ 650	\$ 455.00
Casey Nunez	01/02/20	Conference call with H. Steinberg, I. Hirsch, C. Nunez, D. Krishnamurthy, M. Land, and P. DiMatteo (all KPMG) to discuss initial information request listing and work plan for purposes of determining project strategy and preliminary modeling	0.8	\$ 744	\$ 595.20
Dawn Krishnamurthy	01/02/20	Conference call with H. Steinberg, I. Hirsch, C. Nunez, D. Krishnamurthy, M. Land, and P. DiMatteo (all KPMG) to discuss initial information request listing and work plan for purposes of determining project strategy and preliminary modeling	0.8	\$ 695	\$ 556.00
Howard Steinberg	01/02/20	Conference call with H. Steinberg, I. Hirsch, C. Nunez, D. Krishnamurthy, M. Land, and P. DiMatteo (all KPMG) to discuss initial information request listing and work plan for purposes of determining project strategy and preliminary modeling	0.8	\$ 856	\$ 684.80
Isaac Hirsch	01/02/20	Conference call with H. Steinberg, I. Hirsch, C. Nunez, D. Krishnamurthy, M. Land, and P. DiMatteo (all KPMG) to discuss initial information request listing and work plan for purposes of determining project strategy and preliminary modeling	0.8	\$ 819	\$ 655.20

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Dawn Krishnamurthy	01/03/20	0.9 Review of court filings submitted by Purdue with regards to proposed transaction and potential tax matters to be addressed; 0.2 communication via email with C. Nunez (KPMG) discussing information request/workplan additions; 0.2 Drafted email to I. Hirsch, C. Nunez, M. Land (all KPMG) to provide details related to and copy of updated Workplan.	1.3	\$ 695	\$ 903.50
Tracy Stone	01/03/20	Conference call with H. Steinberg, M. Hoffenberg, T. Stone, I. Hirsch, C. Nunez, P. DiMatteo, P. Kunkel, M. Land, D. Rowles, J. Commisso (all KPMG) to discuss preliminary workplan and initial request list with a focus on trust documents and information necessary for purposes of determining project strategy and preliminary modeling; prepare list of questions related to trust classification (0.8); drafted email to I. Hirsch and C. Nunez re same (0.5).	1.3	\$ 906	\$ 1,177.80
Isaac Hirsch	01/03/20	(0.8) Performed International Tax Managing Director review and concurrently comment on latest version of KPMG workplan draft provided by KPMG M&A team; (0.8) communication via email with T. Stone and P. Kunkel (both KPMG) regarding preparation of list of questions to add to KPMG's information request concerning analysis of the trusts in the Purdue ownership structure	1.6	\$ 819	\$ 1,310.40
Anja Poesl	01/03/20	0.9 Review of Purdue Term Sheet as provided to us by C. Nunez (KPMG) via e-mail dated January 1, 2020 to gain insight regarding planned steps; 0.9 Update Workplan and Information Request List - Germany in excel file, i.e. addition of documents required to prepare German Tax Profile and to perform Transaction Tax Analysis for Germany.	1.8	\$ 750	\$ 1,350.00
Devon Rowles	01/03/20	(1.6) Updates to the workplans sent from KPMG foreign member firms and concurrently revise as needed; (0.3) Discussion with J. Commisso (KPMG) regarding next steps to complete the revenue by country files - as of 1/3/2020.	1.9	\$ 350	\$ 665.00
Michael Land	01/03/20	Reviewed member firm initial information request lists (Israel, Italy, Germany, Netherlands, and China) in conjunction with proposed work plan	2.4	\$ 534	\$ 1,281.60
Isaac Hirsch	01/03/20	(1.3) Continue (from 1/2) to review Norton Rose analysis of high level tax consequences of straw man settlement and concurrently brainstormed with regards to the KPMG cash tax cost model; (0.8) review and concurrently comment on most recent draft of KPMG workplan provided by KPMG M&A team; (0.8) communication via email with T. Stone and P. Kunkel (both KPMG) regarding preparation of list of questions to add to KPMG's information request concerning analysis of the trusts in the Purdue ownership structure.	2.9	\$ 819	\$ 2,375.10

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Jess Commisso	01/07/20	Updated Orion (KPMG share site) to include additional provided by client documentation as of 1/7/2020; (0.4) Updated working group list of broader KPMG team for newest addition of team members pursuant to providing contact information of all engagement participants to internal / external parties; (.6) Updated KPMG share site to include additional KPMG team members to facilitate review of provided by client documentation.	1.8	\$ 350	\$ 630.00
Casey Nunez	01/07/20	Senior manager review of complete draft of workplan included first tier foreign country tax services as requested by client	2.1	\$ 744	\$ 1,562.40
Isaac Hirsch	01/07/20	Continue (from 1/6) to draft details regarding logic related to Purdue Pharma cash tax cost model	2.4	\$ 819	\$ 1,965.60
Dawn Krishnamurthy	01/07/20	(1.1) Perform Manager review of updated global workplan; (1.6) Manager review of updated global information request list including member firms' requests.	2.7	\$ 695	\$ 1,876.50
Dawn Krishnamurthy	01/07/20	Performed analysis regarding Purdue and Mundipharma structure including current status of bankruptcy, ownership, legal claims and global presence - for purposes of identifying and gaining insight regarding key areas of focus (work performed concurrently).	2.8	\$ 695	\$ 1,946.00
Isaac Hirsch	01/07/20	Implement test run of cash tax cost model (for purposes of analyzing the potential cash tax consequences of entity/asset sales) with respect to sale of Switzerland stock or assets	3.2	\$ 819	\$ 2,620.80
Devon Rowles	01/07/20	Continued (from 12/31) to track designated portion of revenue for numerous Mundipharma entities in financial statements for years 2016, 2017, 2018 pursuant to prioritizing jurisdictions for future tax analysis.	3.3	\$ 350	\$ 1,155.00
Ashley Armfield	01/07/20	Outlined inputs that need to be included in cash tax model based on the current version of the workplan as well as additional considerations based on the group's structure.	3.8	\$ 534	\$ 2,029.20
Jess Commisso	01/07/20	Continue (from 1/6) review of assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.	3.9	\$ 350	\$ 1,365.00

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Pete DiMatteo	01/08/20	Conference with T. Giordano and P. DiMatteo (both KPMG) regarding research assignment to determine entitlement to a tax deduction upon the payment of a legal settlement.	0.5	\$ 650	\$ 325.00
Thomas Giordano	01/08/20	Conference with T. Giordano and P. DiMatteo (both KPMG) regarding research assignment to determine entitlement to a tax deduction upon the payment of a legal settlement.	0.5	\$ 350	\$ 175.00
Anja Poesl	01/08/20	Participated in initial call with C. Schmid (KPMG Germany), T. Heubach (KPMG German), A. Poesl and P. Reer (both KPMG US) to align Germany and US teams regarding next steps related to bankruptcy tax consulting project.	0.5	\$ 750	\$ 375.00
Christian Schmid	01/08/20	Participated in initial call with C. Schmid (KPMG Germany), T. Heubach (KPMG German), A. Poesl and P. Reer (both KPMG US) to align Germany and US teams regarding next steps related to bankruptcy tax consulting project.	0.5	\$ 985	\$ 492.50
Philipp Reer	01/08/20	Participated in initial call with C. Schmid (KPMG Germany), T. Heubach (KPMG German), A. Poesl and P. Reer (both KPMG US) to align Germany and US teams regarding next steps related to bankruptcy tax consulting project.	0.5	\$ 765	\$ 382.50
Thomas Heubach	01/08/20	Participated in initial call with C. Schmid (KPMG Germany), T. Heubach (KPMG German), A. Poesl and P. Reer (both KPMG US) to align Germany and US teams regarding next steps related to bankruptcy tax consulting project.	0.5	\$ 750	\$ 375.00
Lukas van der Veen	01/08/20	Manager review of draft document named Preliminary Analysis Sale of the Netherlands prepared by Norton Rose Fulbright, dated November 14, 2019 with focus on legal structure	0.8	\$ 730	\$ 584.00
Aroen Rambhadjan	01/08/20	Partner review of draft document "Preliminary Analysis Sale of the Netherlands" prepared by Norton Rose Fulbright, dated November 14, 2019 with focus on Purdue Pharma legal structure.	0.8	\$ 985	\$ 788.00
Michael Land	01/08/20	(0.3) Review of latest version of workplan and information request list to determine next steps related to bankruptcy tax consulting project; (0.6) Communication to coordinate with KPMG member firm (Netherlands) regarding administration for the anti-money laundering regime	0.9	\$ 534	\$ 480.60
Christian Schmid	01/08/20	Participated in kick-off meeting with T. Heubach and C. Schmid (both KPMG Germany) to discuss documentation received to date, teaming with KPMG US and next steps related to Purdue Pharma tax consulting project.	1.0	\$ 985	\$ 985.00

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
 December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Dawn Krishnamurthy	01/08/20	Review of data room documentation as of 1/8/2020 - for purposes of identifying potential Purdue Pharma tax issues	2.3	\$ 695	\$ 1,598.50
Andy Farinich	01/08/20	Continued (same day) to review designated portion of Purdue Pharma organizational structure documentation provided by client and concurrently organized (in excel) to facilitate creation of a comprehensive global organizational structure chart for further analysis; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	2.5	\$ 534	\$ 1,335.00
Ashley Armfield	01/08/20	Meeting with A. Armfield and J. Commisso (both KPMG) for preliminary discussion related to Purdue cash tax model, focusing on set up, detail inclusion, scenario breakdown, and the end deliverable goal.	2.9	\$ 534	\$ 1,548.60
Jess Commisso	01/08/20	Meeting with A. Armfield and J. Commisso (both KPMG) for preliminary discussion related to Purdue cash tax model, focusing on set up, detail inclusion, scenario breakdown, and the end deliverable goal.	2.9	\$ 350	\$ 1,015.00
Ashley Armfield	01/08/20	Meeting with M. Land, A. Armfield, D. Krishnamurthy (all KPMG) to discuss preliminary cash tax model considerations and the various inputs necessary for purposes of project strategy	3.1	\$ 534	\$ 1,655.40
Dawn Krishnamurthy	01/08/20	Meeting with M. Land, A. Armfield, D. Krishnamurthy (all KPMG) to discuss preliminary cash tax model considerations and the various inputs necessary for purposes of project strategy	3.1	\$ 695	\$ 2,154.50
Michael Land	01/08/20	Meeting with M. Land, A. Armfield, D. Krishnamurthy (all KPMG) to discuss preliminary cash tax model considerations and the various inputs necessary for purposes of project strategy	3.1	\$ 534	\$ 1,655.40
Pete DiMatteo	01/08/20	Perform analysis regarding entitlement to potential tax deductions (including sections 162 and 165) arising from settlement payments made by Purdue and/or its owners under alternate scenarios (e.g., payments from trusts and/or partnerships).	3.4	\$ 650	\$ 2,210.00

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Andy Farinich	01/08/20	Began to review designated portion of Purdue Pharma organizational structure documentation provided by client and concurrently organized (in excel) to facilitate creation of a comprehensive global organizational structure chart for further analysis; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	3.9	\$ 534	\$ 2,082.60
Jess Commisso	01/08/20	Continue (from 1/7) to review assigned portion of numerous Mundipharma entities' financial statements to create a revenue breakdown pursuant to prioritizing jurisdictions for engagement of additional KPMG member firms.	3.9	\$ 350	\$ 1,365.00
Thomas Giordano	01/08/20	Continue, from 1/7, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	3.9	\$ 350	\$ 1,365.00
Isaac Hirsch	01/09/20	Communication via email with P. DiMatteo (KPMG) regarding preparation of organizational charts for purposes of analyzing potential cash tax cost of settlement	0.5	\$ 819	\$ 409.50
Michael Land	01/09/20	Meeting with D. Rowles (KPMG) to review the Purdue Pharma structure deck (for the term sheet) and concurrently discuss possible revisions	0.6	\$ 534	\$ 320.40
Devon Rowles	01/09/20	Meeting with M. Land (KPMG) to review the Purdue Pharma structure deck (for the term sheet) and concurrently discuss possible revisions	0.6	\$ 350	\$ 210.00
Andy Farinich	01/09/20	Continued (from earlier in the day) to review designated Purdue Pharma organizational structure documentation provided by client and concurrently organized (in excel) to facilitate creation of a comprehensive global organizational structure chart for further analysis; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	0.7	\$ 534	\$ 373.80

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	01/09/20	Began to create designated portion of overall jurisdiction prioritization for Mundipharma entities - based on company personnel information provided by the client - pursuant to the engagement of additional KPMG member firms.	2.1	\$ 350	\$ 735.00
Devon Rowles	01/09/20	Continue (from 1/8) creating a structure deck for the drafted term sheet to illustrate the sale of the Mundipharma entities	2.1	\$ 350	\$ 735.00
Thomas Giordano	01/09/20	Performed research to determine entitlement to a tax deduction for settlement payments	2.5	\$ 350	\$ 875.00
Thomas Giordano	01/09/20	Continue, from earlier in the day, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	2.8	\$ 350	\$ 980.00
Ashley Armfield	01/09/20	Meeting with C. Nunez, D. Krishnamurthy, A. Armfield, M. Land (all KPMG) to discuss cash tax model, inputs, and reference tabs to develop an efficient preliminary cash tax model for purposes of project management	3.1	\$ 534	\$ 1,655.40
Casey Nunez	01/09/20	Meeting with C. Nunez, D. Krishnamurthy, A. Armfield, M. Land (all KPMG) to discuss cash tax model, inputs, and reference tabs to develop an efficient preliminary cash tax model for purposes of project management	3.1	\$ 744	\$ 2,306.40
Dawn Krishnamurthy	01/09/20	Meeting with C. Nunez, D. Krishnamurthy, A. Armfield, M. Land (all KPMG) to discuss cash tax model, inputs, and reference tabs to develop an efficient preliminary cash tax model for purposes of project management	3.1	\$ 695	\$ 2,154.50
Michael Land	01/09/20	Meeting with C. Nunez, D. Krishnamurthy, A. Armfield, M. Land (all KPMG) to discuss cash tax model, inputs, and reference tabs to develop an efficient preliminary cash tax model for purposes of project management	3.1	\$ 534	\$ 1,655.40
Pete DiMatteo	01/09/20	Continue (from previous day) to perform analysis regarding entitlement to potential tax deductions (including sections 162 and 165) arising from settlement payments made by Purdue and/or its owners under alternate scenarios (e.g., payments from trusts and/or partnerships).	3.2	\$ 650	\$ 2,080.00

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Andy Farinich	01/14/20	Continued (from 1/13) creating a visual representation of the Norton Rose Calculations and incorporated cash-flows on the org. charts provided by client; <u>Note</u> : this is a very large task because cash-flow depictions were made on PDF organizational charts (approximately 20 provided by client) to depict the flow of cash as a result of the scenario described in the Norton Rose Calculation and some scenarios depicted up to 25 steps, each of which was to be depicted on the corresponding organizational chart. The 20 scenarios compared and contrasted, from a dollar perspective, the differences between an asset sale versus stock sale of certain entities and the associated tax implications under each scenario and included where cash was moving - as a result of the particular scenario.	3.9	\$ 534	\$ 2,082.60
Jess Commisso	01/14/20	Mapping out sale calculations of Mundipharma MEA and Mundipharma DC BV with focus on where values are derived from / where clarification from client is necessary.	3.9	\$ 350	\$ 1,365.00
Ashley Armfield	01/14/20	Meeting with M. Land and A. Armfield (both KPMG) to continue (from same day) discussions regarding preparation of cash tax model for purposes of project strategy and cash flow for Switzerland	3.9	\$ 534	\$ 2,082.60
Michael Land	01/14/20	Meeting with M. Land and A. Armfield (both KPMG) to continue (from same day) discussions regarding preparation of cash tax model for purposes of project strategy and cash flow for Switzerland	3.9	\$ 534	\$ 2,082.60
Ashley Armfield	01/14/20	Meeting with M. Land and A. Armfield (both KPMG) to discuss preparation of cash tax model for purposes of project strategy and cashflow on general inputs tabs	3.9	\$ 534	\$ 2,082.60
Michael Land	01/14/20	Meeting with M. Land and A. Armfield (both KPMG) to discuss preparation of cash tax model for purposes of project strategy and cashflow on general inputs tabs	3.9	\$ 534	\$ 2,082.60
Devon Rowles	01/14/20	Performed tax research in Westlaw, BNA, etc. pursuant to writing a draft memo regarding the deductibility of restitution payments	3.9	\$ 350	\$ 1,365.00

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Thomas Giordano	01/14/20	Continue, from earlier in the day, to review assigned portion of Purdue organizational structure materials (provided by client) and concurrently organized in excel format to facilitate use of data in the creation of an overall organization structure chart; <u>Note</u> : this was an extremely large task with review that included 3 different sources of client organizational information to compile a comprehensive listing of numerous Purdue entities, spanning 60 jurisdictions, while concurrently determining each entities relevant owner / ownership percentage.	4.1	\$ 350	\$ 1,435.00
Karen Erickson	01/15/20	Conference call with P. DiMatteo, T. Giordano and K. Erickson (all KPMG) to discuss the excel formatted global organization structure to facilitate creation of a global organization structure chart.	0.4	\$ 690	\$ 276.00
Pete DiMatteo	01/15/20	Conference call with P. DiMatteo, T. Giordano and K. Erickson (all KPMG) to discuss the excel formatted global organization structure to facilitate creation of a global organization structure chart.	0.4	\$ 650	\$ 260.00
Thomas Giordano	01/15/20	Conference call with P. DiMatteo, T. Giordano and K. Erickson (all KPMG) to discuss the excel formatted global organization structure to facilitate creation of a global organization structure chart.	0.4	\$ 350	\$ 140.00
Devon Rowles	01/15/20	Continue - on same day - to analyze provided by client documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow - as began on same day.	0.6	\$ 350	\$ 210.00
Devon Rowles	01/15/20	Continued, from earlier in the day, to perform tax research in Westlaw, BNA, etc. pursuant to writing a draft memo regarding the deductibility of restitution payments.	0.6	\$ 350	\$ 210.00
Pete DiMatteo	01/15/20	Continued (from 1/14) to review of entity-specific organization charts to create an excel based global organization chart for purposes of generating global organization charts consisting of numerous Purdue Pharma entities	1.1	\$ 650	\$ 715.00
Ashley Armfield	01/15/20	Creating US Tax calculation tab in the cash tax model to calculate individual shareholder taxation for US federal income and state tax purposes (flowing from Foreign tax credits tab).	1.9	\$ 534	\$ 1,014.60

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Sonia Stricker	01/15/20	Compiled information on tax profile, tax compliance status (years for which tax returns have been filed and assessed, open tax years, tax payments), tax audit status (tax years covered by the audit, open tax years) for entities 6 - 8 for years 2016 - 2018 and for entry 9 for year 2016 based on the financial statements provided.	2.0	\$ 380	\$ 760.00
Dawn Krishnamurthy	01/15/20	2.2 Review of PLCONV_LEG_LR 10.12.19.xlsx, tax litigation file, Project Malta Reports, EY flowchart, Term Sheet, etc. (performed concurrently to cross-check information) in preparation for Norton Rose meeting.	2.2	\$ 695	\$ 1,529.00
Jess Commisso	01/15/20	Continued (same day) to analyze assigned portion of PBC documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow; this task required a detailed analysis of cash flow calculations related to the sales of a total of 8 Mundipharma entities.	2.4	\$ 350	\$ 840.00
Sonia Stricker	01/15/20	Compiled information on tax profile, tax compliance status (years for which tax returns have been filed and assessed, open tax years, tax payments), tax audit status (tax years covered by the audit, open tax years) for entities 1 - 5 for years 2016 - 2018 based on the financial statements provided.	2.5	\$ 380	\$ 950.00
Dawn Krishnamurthy	01/15/20	1.2 Manager review of draft Organization Listing compiled - with focus on Mundipharma structure; 1.4 Manager review of material jurisdiction calculations (including supporting information); 0.2 Manager review of draft email regarding deductibility of restitution payments	2.8	\$ 695	\$ 1,946.00
Ashley Armfield	01/15/20	1.9 Updating cash tax model to include Mundipharma Singapore Holding Pte. Limited disposition scenario; 0.9 Updated cash tax model in preparation for manager review / external presentation.	2.8	\$ 534	\$ 1,495.20
Casey Nunez	01/15/20	Finalized updates to initial information request list based on virtual data room review	2.8	\$ 744	\$ 2,083.20
Dawn Krishnamurthy	01/15/20	Performed Manager review of Independent Affiliated Company (IAC) combined structure file	2.8	\$ 695	\$ 1,946.00
Ashley Armfield	01/15/20	Updating foreign tax credits calculation tab in the cash tax model to serve as a baseline for future calculations pursuant to forecasting expected cash taxes.	2.8	\$ 534	\$ 1,495.20
Ashley Armfield	01/15/20	1.7 Updating cash tax model to include Napp Pharmaceutical Holdings Limited disposition scenario; 1.2 Updating cash tax model to include Mundipharma Deutschland GmbH & Co. KG disposition scenario.	2.9	\$ 534	\$ 1,548.60

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Jess Commisso	01/15/20	Revised the cash tax model by including assumptions / updated Mundipharma entity data to develop disposition strategies of Mundipharma entities.	2.9	\$ 350	\$ 1,015.00
Michael Land	01/15/20	2.4 Senior associate review of summary of deduction analysis under Code section 162 for purposes of gaining insight regarding the deductibility of settlement payments; 0.6 review of information request list / virtual data room documentation to determine if additional information was provided as of 1/15/2020; 0.2 Performed Senior Associate review of most recent round of assumptions for Purdue cash tax model as of 1/15/2020.	3.2	\$ 534	\$ 1,708.80
Renay Gosen	01/15/20	Research section 170 charitable contribution deduction in relation to writing memo showing whether settlement payments to the public could be categorized as a "charitable contribution."	3.2	\$ 350	\$ 1,120.00
Devon Rowles	01/15/20	Analyzed designated portion of provided by client documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow.	3.9	\$ 350	\$ 1,365.00
Jess Commisso	01/15/20	Began to analyze assigned portion of provided by client (PBC) documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow; this task required a detailed analysis of cash flow calculations related to the sales of a total of 8 Mundipharma entities.	3.9	\$ 350	\$ 1,365.00
Devon Rowles	01/15/20	Continue (from previous day) to perform tax research in Westlaw, BNA, etc. pursuant to writing a draft memo regarding the deductibility of restitution payments	3.9	\$ 350	\$ 1,365.00
Jess Commisso	01/15/20	Continue, on same day, to analyze assigned portion of PBC documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow; this task required a detailed analysis of cash flow calculations related to the sales of a total of 8 Mundipharma entities.	3.9	\$ 350	\$ 1,365.00
Jess Commisso	01/15/20	Continued (from earlier in the day) to analyze assigned portion of PBC documentation involving an asset versus stock sale calculation of various Mundipharma entities to provide clarification on cash flow; this task required a detailed analysis of cash flow calculations related to the sales of a total of 8 Mundipharma entities.	3.9	\$ 350	\$ 1,365.00
Devon Rowles	01/15/20	Draft memo regarding the deductibility of restitution payments for a more-likely-than-not tax position.	3.9	\$ 350	\$ 1,365.00

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Dawn Krishnamurthy	01/16/20	Participated in post-Norton Rose debrief meeting with H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) for the purpose of addressing issues raised by Debevoise and Norton Rose, including scope of analysis and availability of tax information	0.3	\$ 695	\$ 208.50
Howard Steinberg	01/16/20	Participated in post-Norton Rose debrief meeting with H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) for the purpose of addressing issues raised by Debevoise and Norton Rose, including scope of analysis and availability of tax information	0.3	\$ 856	\$ 256.80
Isaac Hirsch	01/16/20	Participated in post-Norton Rose debrief meeting with H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) for the purpose of addressing issues raised by Debevoise and Norton Rose, including scope of analysis and availability of tax information	0.3	\$ 819	\$ 245.70
Mark Hoffenberg	01/16/20	Participated in post-Norton Rose debrief meeting with H. Steinberg, M. Hoffenberg, I. Hirsch and D. Krishnamurthy (all KPMG) for the purpose of addressing issues raised by Debevoise and Norton Rose, including scope of analysis and availability of tax information	0.3	\$ 980	\$ 294.00
Sonia Stricker	01/16/20	Meeting with S. Stricker and T. Heubach (both KPMG) to update information request list based on data received to date and add additional required documents.	1.0	\$ 380	\$ 380.00
Thomas Heubach	01/16/20	Meeting with S. Stricker and T. Heubach (both KPMG) to update information request list based on data received to date and add additional required documents.	1.0	\$ 750	\$ 750.00
Michael Land	01/16/20	0.3 Updates to Purdue cash tax model with regards to German foreign branch tax; 0.8 review of updated information request list received.	1.1	\$ 534	\$ 587.40
Thomas Giordano	01/16/20	Continue (same day) to conduct research to determine entitlement to a tax deduction for settlement payments including review and analysis of statutory and common law.	1.1	\$ 350	\$ 385.00
Dawn Krishnamurthy	01/16/20	1.0 Review of data room documentation for purpose of gaining an understanding regarding tax exam/audit profile of Canada, China, Germany, Israel, Italy, Netherlands, South Korea, Switzerland, UK; 0.4 Review of Project Malta reports.	1.4	\$ 695	\$ 973.00
Christian Schmid	01/16/20	Partner review of interim collection of data prepared by T. Heubach and S. Stricker (both KPMG Germany).	1.4	\$ 985	\$ 1,379.00

Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Jess Commisso	01/17/20	Review of documentation in virtual data room as of 1/17/2020 to determine if we need to request the client provided structure charts, trust documentation or partnership agreements pursuant to further diligence of Mundipharma entities.	2.8	\$ 350	\$ 980.00
Casey Nunez	01/17/20	0.8 Senior manager review of updated information request list based on feedback from January 16th meeting with Norton Rose and Debevoise; 1.9 review of new Purdue Pharma documentation available in data room as of 1/17; 0.6 review of sell side diligence report for Project Malta.	3.3	\$ 744	\$ 2,455.20
Dawn Krishnamurthy	01/17/20	Review of structure charts / financial statements to gain insight regarding tax impacts of potential sale scenarios in high priority jurisdictions.	3.3	\$ 695	\$ 2,293.50
Thomas Giordano	01/17/20	Performed research to determine rules surrounding foreign tax payments and potential tax benefits to be obtained from such payments.	3.9	\$ 350	\$ 1,365.00
Howard Steinberg	01/18/20	Partner review of virtual data room information received as of 1/18/20 for purposes of determining relevant tax information available.	1.0	\$ 856	\$ 856.00
Dawn Krishnamurthy	01/18/20	Continue, from earlier in the day, to review documentation in the Norton Rose data room for purpose of determining most significant jurisdictions/identifying areas of focus.	1.4	\$ 695	\$ 973.00
Dawn Krishnamurthy	01/18/20	Review of information provided in the Norton Rose data room as of 1/18/20, including Project Malta reports, financial statements and litigation summaries with regards to updating the information request list.	2.8	\$ 695	\$ 1,946.00
Dawn Krishnamurthy	01/18/20	Continued (same day) to review documents provided in data room as of 1/18/20 for purposes of updating / tailoring the information request list.	3.1	\$ 695	\$ 2,154.50
Howard Steinberg	01/19/20	Perform Partner review of financial statement summary for purposes of gaining insight regarding tax posture	1.5	\$ 856	\$ 1,284.00
Dawn Krishnamurthy	01/19/20	Review of financial statements provided in Norton Rose data room for purposes of updating information request list.	3.4	\$ 695	\$ 2,363.00
Pete DiMatteo	01/20/20	Conference call with P. DiMatteo and T. Giordano (both KPMG) discussing the rules surrounding foreign tax payments and potential tax benefits to be obtained from such payments.	0.4	\$ 650	\$ 260.00
Thomas Giordano	01/20/20	Conference call with P. DiMatteo and T. Giordano (both KPMG) discussing the rules surrounding foreign tax payments and potential tax benefits to be obtained from such payments.	0.4	\$ 350	\$ 140.00

Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Casey Nunez	01/20/20	Performed Senior manager review of data room findings for purposes of updating Purdue Pharma information request list.	2.1	\$ 744	\$ 1,562.40
Dawn Krishnamurthy	01/20/20	Performed review of data room documentation as of 1/20 with focus on global structure.	2.3	\$ 695	\$ 1,598.50
Jess Commisso	01/20/20	Performed analysis to determine whether assigned portion of Purdue financial statements are audited versus unaudited for member firm Mundipharma entities - pursuant to correspondence with member firms to request their review of such documentation.	2.6	\$ 350	\$ 910.00
Michael Land	01/20/20	0.7 Review of correspondence with KPMG Germany regarding tax reserve / audits to gain insight regarding German tax profile; 0.7 review of correspondence with KPMG Korea regarding tax reserve / audits to gain insight regarding Korean tax profile; 0.7 review of correspondence with KPMG UK regarding tax reserve / audits to gain insight regarding UK tax profile; 0.6 review of correspondence with KPMG China re tax reserve / audits to gain insight regarding Chinese tax profile	2.7	\$ 534	\$ 1,441.80
Dawn Krishnamurthy	01/20/20	0.7 Review of tax exam history described in meeting notes, E&Y Flowchart, Litigation Summaries and Project Malta due diligence report for purpose of identifying material tax exams (performed concurrently); 1.3 Manager review of financial statements provided in data room with focus on materiality; 0.8 Manager review of information request list as well as information received to date with respect to Swiss / South Korean updates.	2.8	\$ 695	\$ 1,946.00
Maggie Scully	01/20/20	Comparing the information request list to the virtual data room to ensure KPMG US team has accurately accounted for all provided by client information received to date.	3.1	\$ 350	\$ 1,085.00
Devon Rowles	01/20/20	Analysis to determine whether designated portion of Purdue financial statements are audited versus unaudited for my designated portion of member firm Mundipharma entities - pursuant to correspondence with member firms to request their review of such documentation.	3.4	\$ 350	\$ 1,190.00
Thomas Giordano	01/20/20	Continued (same day) to perform research to determine rules surrounding foreign tax payments and potential tax benefits to be obtained from such payments	3.6	\$ 350	\$ 1,260.00
Jess Commisso	01/20/20	Compiling the organizational charts of all Mundipharma entities provided by the client into a single file pursuant to mapping out relationships between jurisdictions and the global organizational chart.	3.9	\$ 350	\$ 1,365.00

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Karen Erickson	01/22/20	Provide import templates as well as sample organizational charts for consideration to P. DiMatteo and T. Giordano (0.2); Initiated alternate sorting of entities to mitigate separation of parent and sub in chart where possible (0.6)	0.8	\$ 690	\$ 552.00
Dawn Krishnamurthy	01/22/20	0.8 Review of most recent data uploaded to Norton Rose data room as of 1/22/2020 to identify tax relevant items; 0.2 Performed Manager review of draft email prepared by A. Armfield (KPMG) to be sent to KPMG Swiss member firm for purpose of engaging Swiss team to perform services for Purdue.	1.0	\$ 695	\$ 695.00
Oron Zeevi	01/22/20	Drafted email to J. Commisso (KPMG US) detailing initial findings following the review of the financial statements with respect to tax reserves, tax attributes, etc.	1.0	\$ 450	\$ 450.00
Arik Eytan	01/22/20	Partner level review of the 2016 - 2018 financial statements of the Purdue Pharma Israeli entity in order to assess available tax reserves, tax attributes, operations and financial results.	1.0	\$ 555	\$ 555.00
Pete DiMatteo	01/22/20	Continue (same day) to perform analysis related to the deductibility of settlement payments - relating to contemplated payments made by trusts/individual beneficiaries to the settlement vehicle under section 162.	1.5	\$ 650	\$ 975.00
Thomas Heubach	01/22/20	Review of audited financial statements (including related findings) of S. Stricker (KPMG Germany) related to quantified tax audit adjustments requested by D. Krishnamurthy (KPMG US) for Purdue entities Mundipharma Deutschland GmbH & Co. KG and Mundipharma GmbH	1.7	\$ 750	\$ 1,275.00
Pete DiMatteo	01/22/20	Review of legal entity manager output for purposes of creating a global organization chart	1.8	\$ 650	\$ 1,170.00
Madeleine Latham	01/22/20	Meeting with A. Desai (KPMG UK) to analyze and concurrently discuss the accounts for the Purdue UK companies in scope in order to identify tax reserves, open tax audits or controversies, and tax attributes, as requested by KPMG US in an email dated 01/21/20. Note: two individuals performed this task given the volume of material to analyze (for 15 companies across three financial years) and the deadline set by KPMG US.	2.0	\$ 380	\$ 760.00

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Dawn Krishnamurthy	01/22/20	1.1 Review of Norton Rose data room financial statements in conjunction with Advance Pricing Agreement (APA) agreements for purpose of updating information request list; 1.6 Manager review of trust research performed by J. Commisso (KPMG); 0.8 Manager review of German audit exposure issue for purpose of drafting follow-up email to German team.	3.5	\$ 695	\$ 2,432.50
Dawn Krishnamurthy	01/22/20	2.9 Perform analysis related to trust / disregarded entity tax treatment for purposes of understanding treatment of potential distribution of Mundipharma sales proceeds; 0.4 Performed analysis related to Section 481 adjustments with regards to Purdue Pharma tax matter; 0.4 performed additional analysis regarding ownership of Pharmaceutical Research Associates Taiwan Inc. for risk management purposes.	3.7	\$ 695	\$ 2,571.50
Jess Commisso	01/22/20	Began to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes. <u>Note</u> : this is an exceptionally large task that will be ongoing including continuous updates to the deck (based on additional data received) and will be performed by several KPMG professionals assigned to different facets of structure deck.	3.9	\$ 350	\$ 1,365.00
Thomas Giordano	01/22/20	Began to cross-check LEM created global organization structure chart (related to numerous Purdue Pharma entities) with excel formatted organization structure to determine accuracy of overall global organization structure.	3.9	\$ 350	\$ 1,365.00
Thomas Giordano	01/22/20	Continue, same day, to cross-check LEM created global organization structure chart (related to numerous Purdue Pharma entities) with excel formatted organization structure to determine accuracy of overall global organization structure.	3.9	\$ 350	\$ 1,365.00
Pete DiMatteo	01/22/20	Performed analysis related to the deductibility of settlement payments - relating to contemplated payments made by trusts/individual beneficiaries to the settlement vehicle under section 162.	3.9	\$ 650	\$ 2,535.00
Jonas Lau	01/22/20	Meeting with G. Bell and S. Tyler (both KPMG Canada) to discuss results of reviews related to Purdue Canadian entities, Canadian organizational charts and available financial statements.	0.5	\$ 614	\$ 307.00
Sam Tyler	01/22/20	Meeting with G. Bell and S. Tyler (both KPMG Canada) to discuss results of reviews related to Purdue Canadian entities, Canadian organizational charts and available financial statements.	0.5	\$ 743	\$ 371.50

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
 December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Gregory Bell	01/22/20	Meeting with G. Bell and S. Tyler (both KPMG Canada) to discuss results of reviews related to Purdue Canadian entities, Canadian organizational charts and available financial statements.	0.5	\$ 743	\$ 371.50
Sam Tyler	01/22/20	Partner review of all available documentation in data room to consider Canadian tax issues (0.4) and drafted respond to request from KPMG US (0.4)	0.8	\$ 743	\$ 594.40
Christin Witt	01/23/20	Call with T. Heubach, P. Reer and C. Witt (KPMG German team) to discuss status of German tax analysis and next steps as of 1/23/2020.	0.4	\$ 650	\$ 260.00
Philipp Reer	01/23/20	Call with T. Heubach, P. Reer and C. Witt (KPMG German team) to discuss status of German tax analysis and next steps as of 1/23/2020.	0.4	\$ 765	\$ 306.00
Anja Poesl	01/23/20	Call with T. Heubach, P. Reer and C. Witt (KPMG German team) to discuss status of German tax analysis and next steps as of 1/23/2020.	0.4	\$ 750	\$ 300.00
Thomas Giordano	01/23/20	Continue, on same day, to create assigned portion of global organization structure related to numerous Purdue Pharma entities in Visio leveraging LEM created global organization structure	0.5	\$ 350	\$ 175.00
Jess Commisso	01/23/20	Continued (from 1/21) to research types of trusts, taxation of trusts, as well as details on Jersey trusts, while simultaneously creating notes for distribution to the rest of the team, pursuant to trust analysis.	0.8	\$ 350	\$ 280.00
Isaac Hirsch	01/23/20	Participate in call with I. Hirsch, P. DiMatteo K. Erickson, and T. Giordano (all KPMG) regarding questions as well as recommendations for data presentation in LEM for efficient charting alternatives.	0.9	\$ 819	\$ 737.10
Karen Erickson	01/23/20	Participate in call with I. Hirsch, P. DiMatteo K. Erickson, and T. Giordano (all KPMG) regarding questions as well as recommendations for data presentation in LEM for efficient charting alternatives.	0.9	\$ 690	\$ 621.00
Pete DiMatteo	01/23/20	Participate in call with I. Hirsch, P. DiMatteo K. Erickson, and T. Giordano (all KPMG) regarding questions as well as recommendations for data presentation in LEM for efficient charting alternatives.	0.9	\$ 650	\$ 585.00
Thomas Giordano	01/23/20	Participate in call with I. Hirsch, P. DiMatteo K. Erickson, and T. Giordano (all KPMG) regarding questions as well as recommendations for data presentation in LEM for efficient charting alternatives.	0.9	\$ 350	\$ 315.00

Bankruptcy Tax Consulting Services
December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Dawn Krishnamurthy	01/23/20	Performed analysis regarding ownership structure of Mundipharma entities with focus on tax issues related to distribution of sales proceeds.	1.2	\$ 695	\$ 834.00
Ashley Armfield	01/23/20	Discussion with C. Nunez, I. Hirsch, D. Krishnamurthy, A. Armfield, J. Commisso (all KPMG) regarding cash tax model set up and structure deck illustration pursuant to Mundipharma MEA GmbH (Switzerland) entity analysis	1.3	\$ 534	\$ 694.20
Casey Nunez	01/23/20	Discussion with C. Nunez, I. Hirsch, D. Krishnamurthy, A. Armfield, J. Commisso (all KPMG) regarding cash tax model set up and structure deck illustration pursuant to Mundipharma MEA GmbH (Switzerland) entity analysis	1.3	\$ 744	\$ 967.20
Dawn Krishnamurthy	01/23/20	Discussion with C. Nunez, I. Hirsch, D. Krishnamurthy, A. Armfield, J. Commisso (all KPMG) regarding cash tax model set up and structure deck illustration pursuant to Mundipharma MEA GmbH (Switzerland) entity analysis	1.3	\$ 695	\$ 903.50
Isaac Hirsch	01/23/20	Discussion with C. Nunez, I. Hirsch, D. Krishnamurthy, A. Armfield, J. Commisso (all KPMG) regarding cash tax model set up and structure deck illustration pursuant to Mundipharma MEA GmbH (Switzerland) entity analysis	1.3	\$ 819	\$ 1,064.70
Jess Commisso	01/23/20	Discussion with C. Nunez, I. Hirsch, D. Krishnamurthy, A. Armfield, J. Commisso (all KPMG) regarding cash tax model set up and structure deck illustration pursuant to Mundipharma MEA GmbH (Switzerland) entity analysis	1.3	\$ 350	\$ 455.00
Jess Commisso	01/23/20	Incorporated UK financial statement analysis of tax attributes, reserves and audits into a combined file of all member firm entities pursuant to Mundipharma entity analysis.	1.3	\$ 350	\$ 455.00
Isaac Hirsch	01/23/20	Managing Director review of latest set of updates to organizational charts sent by P. DiMatteo (KPMG)	1.5	\$ 819	\$ 1,228.50
Ashley Armfield	01/23/20	Updated cash tax model structure / data (about the Mundipharma entities as provided in the Norton Rose calculations) for Mundipharma Deutschland GmbH & Co KG to conform with all prior updates.	2.1	\$ 534	\$ 1,121.40
Ashley Armfield	01/23/20	Discussion with J. Commisso, D. Rowles and A. Armfield (all KPMG) regarding cash flow steps involved with the sale of Mundipharma entities, including intercompany rationalization and redemption of preferred shares, to determine tax treatment of associated contributions and distributions pursuant to providing a structure chart in PowerPoint.	2.2	\$ 534	\$ 1,174.80

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	01/24/20	Discussion with J. Commisso, D. Rowles, and A. Armfield (all KPMG) regarding the cash flow steps involved with the sale of Mundipharma MEA GmbH pursuant to providing a structure chart in PowerPoint.	1.6	\$ 350	\$ 560.00
Jess Commisso	01/24/20	Discussion with J. Commisso, D. Rowles, and A. Armfield (all KPMG) regarding the cash flow steps involved with the sale of Mundipharma MEA GmbH pursuant to providing a structure chart in PowerPoint.	1.6	\$ 350	\$ 560.00
Ashley Armfield	01/24/20	Drafting template and corresponding email discussing structure deck outline for potential dispositions to be send to KPMG project team (i.e., P. DiMatteo, I. Hirsch, C. Nunez).	1.6	\$ 534	\$ 854.40
Devon Rowles	01/24/20	Finalized outline to cover tax research around the deductibility of restitution payments - continued from 1/23.	1.8	\$ 350	\$ 630.00
Ashley Armfield	01/24/20	Discussion with D. Rowles and A. Armfield (both KPMG) regarding the cash flow steps involved with the sale of Purdue Pharma (Canada) pursuant to providing a structure chart in PowerPoint.	2.1	\$ 534	\$ 1,121.40
Devon Rowles	01/24/20	Discussion with D. Rowles and A. Armfield (both KPMG) regarding the cash flow steps involved with the sale of Purdue Pharma (Canada) pursuant to providing a structure chart in PowerPoint.	2.1	\$ 350	\$ 735.00
Jess Commisso	01/24/20	Continued, from previous day, to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes	2.5	\$ 350	\$ 875.00
Thomas Giordano	01/24/20	Continued (from 1/23) to create assigned portion of global organization structure related to numerous Purdue Pharma entities in Visio leveraging LEM created global organization structure.	2.7	\$ 350	\$ 945.00
Dawn Krishnamurthy	01/24/20	1.3 Review of Project Malta financial due diligence reports with focus on vendor due diligence findings; 0.1 Review new document "FW IAC Follow Up Requests.msg" in Norton Rose Data Room; 1.1 Review of terms of Purdue transfer of assets to Newco in term sheet; 0.3 Manager review of schedule of assets and liabilities of Purdue Pharma LP for tax liens/liabilities.	2.8	\$ 695	\$ 1,946.00
Dawn Krishnamurthy	01/24/20	2.6 Drafted summary of tax relevant information contained in Project Malta Report Volume 1 (report was over 400 pages); 0.2 Manager review of Project Malta summary prepared by M. Land (KPMG).	2.8	\$ 695	\$ 1,946.00

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Dawn Krishnamurthy	01/24/20	1.2 Review of Debtors Informational Brief filed by Purdue with focus on whether the organizational structure had been disclosed as well as what payments were going to be required (and from which entities) in order to gain insight regarding where the cash needs to move within the structure to identify potential tax issues); 2.0 Perform research regarding proposed settlement as described in bankruptcy court filings	3.2	\$ 695	\$ 2,224.00
Isaac Hirsch	01/24/20	(1.4) Continued (from 1/23) Managing Director review of updates to organizational charts sent by P. DiMatteo (KPMG) (2.3) Drafted comments related to cash tax model to account for rate disparity rules	3.7	\$ 819	\$ 3,030.30
Pete DiMatteo	01/24/20	Continued (from 1/23) to draft and concurrently analyze organizational structures necessary to create PowerPoint slides depicting potential transactions related to the contemplated Mundipharma sales (16 potential sale scenarios).	3.8	\$ 650	\$ 2,470.00
Jess Commisso	01/24/20	Continue (same day) to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes - as began earlier in the day.	3.9	\$ 350	\$ 1,365.00
Thomas Giordano	01/24/20	Continued (from earlier in the day) to create assigned portion of global organizational structure related to numerous Purdue Pharma entities in Visio leveraging LEM created global organization structure.	3.9	\$ 350	\$ 1,365.00
Thomas Giordano	01/24/20	Continued (from same day) to create global organizational structure related to numerous Purdue Pharma entities in Visio leveraging LEM created global organization structure.	3.9	\$ 350	\$ 1,365.00
Andy Farinich	01/24/20	Continued, from earlier in the day, to create a Visio file depicting designated portion of the global organizational structure, of numerous Purdue Pharma entities, leveraging the LEM global organization file (task not completed)	1.5	\$ 534	\$ 801.00
Andy Farinich	01/24/20	Continue, from previous day, to create a Visio file depicting designated portion of the global organizational structure, of numerous Purdue Pharma entities, leveraging the LEM global organization file (task not completed)	3.9	\$ 534	\$ 2,082.60
Andy Farinich	01/24/20	Continued, same day, to create a Visio file depicting designated portion of the global organizational structure, of numerous Purdue Pharma entities, leveraging the LEM global organization file (task not completed)	3.9	\$ 534	\$ 2,082.60
Dawn Krishnamurthy	01/26/20	Review of Project Malta report Volume 1 for purpose of identifying potential tax exposures.	0.8	\$ 695	\$ 556.00

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Thomas Giordano	01/29/20	Continue (on same day) additional development structure deck disposition scenarios for Napp Pharmaceutical Holdings Limited.	1.1	\$ 350	\$ 385.00
Thomas Giordano	01/29/20	Continued (same day) additional development of structure deck disposition scenarios regarding Mundipharma Medical Company Limited	1.1	\$ 350	\$ 385.00
Ashley Armfield	01/29/20	Meeting with A. Armfield and M. Land (all KPMG) to discuss structuring alternative scenarios with regards to overall strategy	1.1	\$ 534	\$ 587.40
Michael Land	01/29/20	Meeting with A. Armfield and M. Land (all KPMG) to discuss structuring alternative scenarios with regards to overall strategy	1.1	\$ 534	\$ 587.40
Ashley Armfield	01/29/20	Meeting with A. Armfield and M. Land (all KPMG) to discuss structuring alternatives related to Mundipharma MEA GmbH.	1.2	\$ 534	\$ 640.80
Michael Land	01/29/20	Meeting with A. Armfield and M. Land (all KPMG) to discuss structuring alternatives related to Mundipharma MEA GmbH.	1.2	\$ 534	\$ 640.80
Isaac Hirsch	01/29/20	Communication via email with P. DiMatteo (KPMG) regarding research related to the deductibility of settlement payments	1.3	\$ 819	\$ 1,064.70
Dawn Krishnamurthy	01/29/20	Review of Purdue Pharma transfer pricing documentation for purpose of identifying potential tax exposures.	1.5	\$ 695	\$ 1,042.50
Pete DiMatteo	01/29/20	Update outline detailing section 162 research for purposes of determining whether a deduction is permissible for settlement payments	1.6	\$ 650	\$ 1,040.00
Ashley Armfield	01/29/20	Meeting with A. Armfield and M. Land (all KPMG) to discuss structuring alternatives related to Mundipharma DC B.V.	2.3	\$ 534	\$ 1,228.20
Michael Land	01/29/20	Meeting with A. Armfield and M. Land (all KPMG) to discuss structuring alternatives related to Mundipharma DC B.V.	2.3	\$ 534	\$ 1,228.20
Devon Rowles	01/29/20	Update the Switzerland structure deck (per direction from A. Armfield and M. Land - both of KPMG) with specific regards to individual country dispositions / tax consequences	2.4	\$ 350	\$ 840.00
Frank Caratzola	01/29/20	0.3 Compiled a listing of the trusts in Client's entity structure and concurrently identified the beneficiaries of each in an excel workbook; 2.3 Performed research regarding foreign tax credit ("FTC") rules under sections 901/904 as they related to the specific entity structures in Client's facts	2.6	\$ 534	\$ 1,388.40
Isaac Hirsch	01/29/20	Performed Managing Director review and concurrently analyze research prepared by P. DiMatteo (KPMG) related to deductibility of settlement payments	2.8	\$ 819	\$ 2,293.20

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Jess Commisso	01/29/20	Continued (from 1/24) to create illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes.	3.9	\$ 350	\$ 1,365.00
Howard Steinberg	01/29/20	Perform Partner review of data room information for purposes of determining tax posture	1.0	\$ 856	\$ 856.00
Thomas Giordano	01/30/20	Continued (same day) to draft detailed email to project team explaining an identified ownership depiction issue regarding four entities in the Mundipharma MEA GmbH organization structure that had effects across multiple entities' organization structures	0.3	\$ 350	\$ 105.00
Thomas Giordano	01/30/20	Continued (same day) to further refine the structure deck disposition scenarios for Mundipharma Medical Company Limited as of 1/30/2020 with respect to new information received as well as updates to layout/format of the deck (which evolves and will continue to evolve) - the layout and presentation of the slide deck is a work in process, therefore, the refinement and revisions will continue to occur for the foreseeable future with respect to these same decks all of which will need to be consistent.	0.5	\$ 350	\$ 175.00
Thomas Giordano	01/30/20	Continue (on same day) to further refine the structure deck disposition scenarios for Mundibiopharma Limited as of 1/30/2020 with respect to new information received as well as updates to layout/format of the deck (which evolves and will continue to evolve - the layout and presentation of the slide deck is a work in process, therefore, the refinement and revisions will continue to occur for the foreseeable future with respect to these same decks all of which will need to consistent).	0.6	\$ 350	\$ 210.00
Thomas Giordano	01/30/20	Began to draft detailed email to project team regarding the identified ownership depiction issue related to four entities in the MundipharmaMEA GmbH organization structure that had effects across multiple entities' organization structures	0.7	\$ 350	\$ 245.00
Michael Land	01/30/20	Review of United Kingdom disposition scenarios for purposes of assessing the optimal structure to maximize distributable proceeds	1.1	\$ 534	\$ 587.40
Dawn Krishnamurthy	01/30/20	Review structure decks for purpose of gaining insight regarding materiality and potential tax issues involved in disposition: Argentina - Bermuda	1.2	\$ 695	\$ 834.00
Michael Land	01/30/20	Review of Singapore cash flow calculation with regards to asset versus stock sale	1.3	\$ 534	\$ 694.20

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Ashley Armfield	01/30/20	Performed structural updates to the cash tax model (based on comments received from I. Hirsch and discussions with M. Land - both KPMG) including the calculation of foreign tax credits and income classification.	2.8	\$ 534	\$ 1,495.20
Michael Land	01/30/20	1.4 Review of Canada disposition scenarios with regards to asset versus stock sale 1.6 Review of Canada cash flow calculation regarding asset versus stock sale	3.0	\$ 534	\$ 1,602.00
Dawn Krishnamurthy	01/30/20	2.1 Review of structure decks for purpose of gaining insight regarding materiality and potential tax issues involved in disposition: France - Japan; 0.9 Review of structure decks for purpose of gaining insight regarding materiality and potential tax issues involved in disposition: Luxembourg - UK.	3.0	\$ 695	\$ 2,085.00
Thomas Giordano	01/30/20	Further refined the structure deck disposition scenarios for Mundibiopharma Limited as of 1/30/2020 with respect to new information received as well as updates to layout/format of the deck (which evolves and will continue to evolve - the layout and presentation of the slide deck is a work in process, therefore, the refinement and revisions will continue to occur for the foreseeable future with respect to these same decks all of which will need to consistent).	3.4	\$ 350	\$ 1,190.00
Pete DiMatteo	01/30/20	Continue, from previous day, to draft PowerPoint presentation depicting contemplated transactions	3.5	\$ 650	\$ 2,275.00
Thomas Giordano	01/30/20	Further refined the structure deck disposition scenarios for Mundipharma Medical Company Limited, as of 1/30/2020, with respect to new information received as well as updates to layout/format of the deck (which evolves and will continue to evolve - the layout and presentation of the slide deck is a work in process, therefore, the refinement and revisions will continue to occur for the foreseeable future with respect to these same decks all of which will need to be consistent).	3.5	\$ 350	\$ 1,225.00
Pete DiMatteo	01/30/20	Continue (from 1/29) to update outline detailing section 162 research to include results of additional research for purposes of determining whether a deduction is permissible for settlement payments.	3.7	\$ 650	\$ 2,405.00
Frank Caratzola	01/30/20	Continued (from 1/29/2020) to perform research regarding foreign tax credit ("FTC") rules under sections 901/904 as they related to the specific entity structures in client's facts	3.7	\$ 534	\$ 1,975.80
Jess Commisso	01/30/20	Continue (same day) to create assigned portion of illustrative structure deck based on Norton Rose sale computations of Mundipharma entities pursuant to sharing with our member firms for sale and tax analysis purposes.	3.9	\$ 350	\$ 1,365.00

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Ashley Armfield	01/31/20	Meeting with K. Krishnamurthy, A. Armfield, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Mundipharma DC BV (Netherlands) asset/stock dispositions and related tax consequences	0.7	\$ 534	\$ 373.80
Nick Morgan	01/31/20	Meeting with K. Krishnamurthy, A. Armfield, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Mundipharma DC BV (Netherlands) asset/stock dispositions and related tax consequences	0.7	\$ 350	\$ 245.00
Devon Rowles	01/31/20	Meeting with K. Krishnamurthy, A. Armfield, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Mundipharma DC BV (Netherlands) asset/stock dispositions and related tax consequences	0.7	\$ 350	\$ 245.00
Michael Land	01/31/20	Meeting with K. Krishnamurthy, A. Armfield, D. Rowles and N. Morgan (all KPMG) to discuss structure decks related to Mundipharma DC BV (Netherlands) asset/stock dispositions and related tax consequences	0.7	\$ 534	\$ 373.80
Jess Commisso	01/31/20	Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to Mundipharma Singapore Holdings Pte. Limited asset/stock dispositions and related tax consequences.	0.7	\$ 350	\$ 245.00
Michael Land	01/31/20	Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to Mundipharma Singapore Holdings Pte. Limited asset/stock dispositions and related tax consequences.	0.7	\$ 534	\$ 373.80
Pete DiMatteo	01/31/20	Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to Mundipharma Singapore Holdings Pte. Limited asset/stock dispositions and related tax consequences.	0.7	\$ 650	\$ 455.00
Thomas Giordano	01/31/20	Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to Mundipharma Singapore Holdings Pte. Limited asset/stock dispositions and related tax consequences.	0.7	\$ 350	\$ 245.00
Jess Commisso	01/31/20	Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to the Mundipharma Medical Company Ltd. (United Kingdom) asset/stock dispositions and related tax consequences	0.7	\$ 350	\$ 245.00
Michael Land	01/31/20	Meeting with P. DiMatteo, M. Land, J. Commisso, T. Giordano (all KPMG) to discuss structure decks related to the Mundipharma Medical Company Ltd. (United Kingdom) asset/stock dispositions and related tax consequences	0.7	\$ 534	\$ 373.80

Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	01/31/20	Extract and concurrently compiled Singapore tax documentation from the virtual data room as of 1/31/2020 to share with Singapore pursuant to their tax analysis.	2.3	\$ 350	\$ 805.00
Dawn Krishnamurthy	01/31/20	2.4 Manager review of Mundipharma ownership structures for purpose of depicting disposition scenarios; 0.3 Review of EY Q&A document (a follow up to the EY financial vendor Due Diligence report which we reviewed for relevant tax information) with entity listing with focus on the IAC listing tab (which I compared to our information on entities in the Mundipharma group) to ensure a complete listing of IAC entities so that we can accurately gain insight regarding which entities may potentially to be sold / where the assets are located.	2.7	\$ 695	\$ 1,876.50
Arpit Kakar	01/31/20	Analyzed audited financial statements (Financial Year 2016-2018) of Modi-Mundipharma Private Limited to determine Tax reserves, Open tax audits or controversies as well as tax attribute carryforwards and concurrently drafted information summary of such details as appearing in the audited financials.	2.8	\$ 640	\$ 1,792.00
Naman Gupta	01/31/20	Analyzed audited financial statements (Financial Year 2016-2018) of Modi-Mundipharma Healthcare Private Limited and Win-Medicare Private Limited to determine Tax reserves, Open tax audits or controversies and Tax attribute carryforwards while concurrently preparing an information summary of same as appearing in the audited financials.	3.1	\$ 640	\$ 1,984.00
Dawn Krishnamurthy	01/31/20	Performed Manager review of Mundipharma draft disposition scenarios deck (Canada).	3.1	\$ 695	\$ 2,154.50
Pete DiMatteo	01/31/20	Draft structuring deck depicting transactions related to Mundipharma Deutschland GmbH & Co. KG (Germany) stock/asset sales and tax consequences	3.3	\$ 650	\$ 2,145.00
Frank Caratzola	01/31/20	Performed research regarding foreign tax credits - as they relate to Purdue Pharma (client) structure	3.4	\$ 534	\$ 1,815.60
Nidhi Jain	01/31/20	Analyzed audited financial statements (Financial Year 2016-2018) of Modi-Mundipharma Beauty Products Private Limited to determine Tax reserves, Open tax audits or controversies and Tax attribute carryforwards; and prepared information summary of such details as appearing in the audited financials.	3.5	\$ 640	\$ 2,240.00
Ashley Armfield	01/31/20	2.9 Performed research related to differential tax rate relating to foreign tax credit calculation pursuant to Purdue Pharma cash tax model; 0.9 Updating cash tax model to incorporate rate differential concept per results of research.	3.8	\$ 534	\$ 2,029.20

Fee Application Preparation Services
December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Wendy Shaffer	01/06/20	0.4 initial communication with A. Armfield (KPMG) regarding Purdue Pharma bankruptcy including information related to use of KPMG member firms and next steps; 0.1 follow-up communication with M. Plangman (KPMG) regarding same; 2.5 begin to draft multiple emails to KPMG foreign member firms including creation of Templates (by country) for inclusion in email to provide US bankruptcy time / expense detail requirements to facilitate filings in the bankruptcy court.	2.9	\$ 202	\$ 585.80
Wendy Shaffer	01/07/20	0.1 Call with P. Reer (KPMG) regarding German KPMG professionals currently working in the US performing services for Purdue Pharma in order to provide correct time/expense timekeeping guidelines and 0.1 forward US SYNC instructions as requested to appropriate team members	0.2	\$ 202	\$ 40.40
Wendy Shaffer	01/08/20	Drafted additional emails to new Purdue team members (US and Foreign member firms) including updates to templates to facilitate billings in the bankruptcy court.	0.5	\$ 202	\$ 101.00
Wendy Shaffer	01/10/20	Draft email to new team members for Purdue as of 1/10/2020 to facilitate billing in the bankruptcy court.	0.2	\$ 202	\$ 40.40
Dawn Krishnamurthy	01/13/20	0.1 Discussion with W. Shaffer (KPMG) regarding services to be billed in KPMG 1st monthly fee application performed by KPMG foreign member firms.	0.1	\$ 695	\$ 69.50
Wendy Shaffer	01/13/20	Discussion with D. Krishnamurthy (KPMG) regarding services to be billed in KPMG 1st monthly fee application performed by KPMG foreign member firms.	0.1	\$ 202	\$ 20.20
Wendy Shaffer	01/13/20	0.2 Updated exhibit C1 of Purdue 1st monthly fee application to include data from KPMG member firms - China and Germany; 0.1 review court docket to extract copy of Purdue ICO, 0.2 Updated exhibit A of Purdue 1st monthly fee application to include additional KPMG team members.	0.5	\$ 202	\$ 101.00
Wendy Shaffer	01/14/20	0.4 begin initial review of documentation email communication to date related to Purdue Pharma bankruptcy; 0.9 begin to create Purdue Pharma 1st monthly fee application exhibits; 0.5 Updated exhibit C1 of Purdue 1st monthly to include data received from KPMG foreign member firms as of 1/14/20.	1.8	\$ 202	\$ 363.60
Wendy Shaffer	01/15/20	Continued, same day, to update exhibit C1 of Purdue Pharma to include data received from professionals as of 1/15/2021.	1.9	\$ 202	\$ 383.80
Wendy Shaffer	01/15/20	Updated exhibit C1 of Purdue Pharma to include data received from professionals as of 1/15/2020	3.8	\$ 202	\$ 767.60

Fee Application Preparation Services
December 23, 2019 through January 31, 2020

Name	Date	Description	Hours	Rate	Amount
Wendy Shaffer	01/17/20	0.1 Review of Purdue Pharma engagement letter with regards to rates to included in 1st monthly fee application- send communication to M. Plangman (KPMG) related to same; 1.6 Updates to exhibit C1 of Purdue Pharma to include data received from professionals as of 1/17/2020; 1.0 Call with M. Plangman (KPMG) regarding initial questions related to Purdue engagement including questions regarding rates, services to be performed by KPMG foreign member firms and related templates to be utilized to capture time and expense detail to be submitted in the bankruptcy court.	2.7	\$ 202	\$ 545.40
Wendy Shaffer	01/22/20	3.2 Updated exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from professionals as of 1/22/20; 0.1 drafted email to G. Flasser and D. Brogan (both Bayard law) re KPMG introduction and questions regarding assistance with filing / service of monthly and interim applications.	3.3	\$ 202	\$ 666.60
Wendy Shaffer	01/27/20	0.3 Review of Purdue Pharma Interim Compensation Order to facilitate billings in the bankruptcy court; 0.3 Draft email to KPMG Partners/team leads to provide copy of ICO and summary of timeline process related to same; 1.8 Updated exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from KPMG professionals as of 1/27/2020	2.4	\$ 202	\$ 484.80
Wendy Shaffer	01/27/20	0.2 Updated exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from KPMG member firm in South Korea as of 1/27/2020; 0.1 email to B. Defliese (KPMG) regarding time detail received for foreign member firms and next steps; 0.2 Reviewed KPMG work in progress reports to confirm billable hours for KPMG through 1/26/2020; 0.1 email to C. Nunez (KPMG) regarding rates to be used in Exhibit A of Purdue Pharma monthly fee applications.	0.6	\$ 202	\$ 121.20
Wendy Shaffer	01/28/20	3.5 Updated to exhibit C1 of Purdue Pharma 1st monthly fee application to include data received from professionals as of 1/22/20; 0.1 call with C. Nunez (KPMG) regarding rates to be included in Purdue Pharma 1st monthly fee application.	3.6	\$ 202	\$ 727.20
Wendy Shaffer	01/28/20	0.1 Follow-up communication via email with C. Nunez (KPMG) regarding rates to be included in Purdue Pharma 1st monthly fee application; 0.2 noted results of discussions with C. Nunez (KPMG) for future reference and go forward; 1.2 Begin to populate rates in Exhibit A of Purdue Pharma 1st monthly fee application per direction from C. Nunez (KPMG)	1.5	\$ 202	\$ 303.00

EXHIBIT D

Purdue Pharma L.P.

Case No. 19-23649

Summary of Out of Pocket Expenses
 December 23, 2019 through January 31, 2020

Category	Amount
Airfare	\$ 170.28
Lodging	\$ 335.95
Meals	\$ 148.68
Ground Transportation	\$ 334.13
Miscellaneous	\$ -
Expense Subtotal	\$ 989.04
Less KPMG Voluntary Reduction as noted on Exhibit D1	\$ (374.11)
Total	\$ 614.93

EXHIBIT D1

Purdue Pharma L.P.

Case No. 19-23649

Detail of Out of Pocket Expenses

December 23, 2019 through January 31, 2020

Name	Date	Description	Amount
Mark Hoffenberg	01/16/20	One way coach class airfare for travel from Washington, DC to New York to attend Purdue client meeting.	\$ 170.28
		Air Fare Subtotal	\$ 170.28
Mark Hoffenberg	01/17/20	Hotel fee incurred on night of 1/16 with check out on 1/17 while traveling to attend Purdue Pharma meeting.	\$ 335.95
		Lodging Subtotal	\$ 335.95
Michael Land	01/10/20	Business Meals: KPMG Participants: A. Armfield, D. Rowles, M. Land	\$ 9.15 ⁽¹⁾
Ashley Armfield	01/13/20	Overtime meals while performing services for Purdue. KPMG Participants: A. Armfield, D. Rowles, J. Commisso, M. Land	\$ 49.97 ⁽¹⁾
Ashley Armfield	01/14/20	Business meals working late team coffee A. Armfield, M. Land, J. Commisso, D. Rowles	\$ 32.56 ⁽¹⁾
Jess Commisso	01/15/20	Overtime meals incurred while performing services for Purdue Pharma. KPMG Participants: A. Armfield, D. Rowles, J. Commisso, M. Land	\$ 57.00
		Meals Subtotal	\$ 148.68
Devon Rowles	01/05/20	Uber fees incurred for travel from office to home while working late on Purdue engagement.	\$ 24.13 ⁽¹⁾
Isaac Hirsch	01/10/20	Parking fee incurred while attending meeting to discuss client business	\$ 30.00 ⁽¹⁾
Michael Land	01/10/20	Uber fee for travel while performing services for Purdue	\$ 34.79 ⁽¹⁾
Ashley Armfield	01/14/20	Uber fee for late night travel from office to home working on client engagement.	\$ 21.65 ⁽¹⁾
Devon Rowles	01/14/20	Uber fees incurred for travel from office to home while working late on Purdue engagement.	\$ 26.01 ⁽¹⁾
Ashley Armfield	01/15/20	Uber fee for late night travel from office to home working on client engagement.	\$ 20.96 ⁽¹⁾
Michael Land	01/15/20	Uber fee for travel while performing services for Purdue	\$ 33.62 ⁽¹⁾
Ashley Armfield	01/16/20	Uber fee for late night travel from office to home working on client engagement.	\$ 18.26 ⁽¹⁾
Isaac Hirsch	01/16/20	Mileage for meeting to discuss client business (14 miles at \$0.575/mile)	\$ 8.05 ⁽¹⁾
Mark Hoffenberg	01/16/20	Uber fee for travel from NYC LaGuardia to hotel in New York City while traveling to attend Purdue client meetings.	\$ 51.70
Mark Hoffenberg	01/17/20	Cab fare incurred in New York City to attend client meeting	\$ 39.96 ⁽¹⁾
Mark Hoffenberg	01/17/20	Parking fees for personal car at airport while traveling to perform services for Purdue.	\$ 25.00 ⁽¹⁾
		Total Ground Transportation	\$ 334.13
		Miscellaneous Subtotal	\$ -
		Subtotal Out of Pocket Expenses	\$ 989.04
		Less KPMG Voluntary Reduction	\$ (374.11) ⁽¹⁾
		Total Out of Pocket Expenses	\$ 614.93

⁽¹⁾ KPMG is taking a voluntary reduction of expenses under \$50.00.